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Imatinib, a small compound that selectively inhibits the ac-
tivity of a limited number of receptor tyrosine kinases, is
currently considered the standard therapy in advanced inoper-
able forms of gastrointestinal stromal tumors (GISTs) [1].
Despite the importance of anti-c-KIT therapeutics, very few
studies have characterized the c-Kit oncogene in adenocarci-
noma of the uterine cervix (adenoca Ut Cx) and the response to
imatinib has not yet been explored, either [2]. Those ﬁndings
prompted us to investigate c-KIT overexpression and activation
as well as the underlying molecular mechanisms in adenoca Ut
Cx, in order to identify possible novel treatment options for this
kind of tumor.
In this study, tissue microarrays (TMAs) were constructed
using a total of 48 formalin-ﬁxed, parafﬁn-embedded specimens
of adenoca Ut Cx. The stem cell factor (SCF) and c-KIT protein
expressions were detected by immunohistochemistry (IHC),
applying previously mentioned monoclonal mouse anti-SCF
and polyclonal rabbit antihuman c-KIT [3]. The c-Kit gene mu-
tations within Exon-2, -8, -9, -11, -13, and -17 were analyzed
by seminested polymerase chain reaction (PCR) and direct* Corresponding author. Department of Pathology, Chung-Shan Medical University an
City 40201, Taiwan.
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were listed elsewhere [4]. Sequence products were analyzed on
an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA).
Inoue et al [2] reported that neither c-KIT receptor nor SCF
ligand were expressed in four (0%), while Went et al [4] demon-
strated c-KIT over-expression in one case out of three (33%) of the
adenoca Ut Cx. Our observations showed that only one (2.08%) out
of the 48 tested cases was c-KIT positive, whereas, the remaining
47 cases were c-KIT negative. This c-KIT positive case exhibited an
intense but focal staining pattern (Figure 1). Fortunately, there
was enough extra tissue material from the only c-KIT-positive case
for a broad spectrum of other ancillary tests. Subsequently, a
negative SCF IHC and absence of c-Kit gene mutations were also
identiﬁed.
Of this selected case of c-KIT positive adenoca Ut Cx, the SCF/c-
KIT loop activation and c-Kit gene activating mutations, which are
speciﬁcally characteristic of GISTs, were not detected. Even though
the precise mechanism of c-KIT over-expression is not yet fully
understood, we suggest that the c-KIT signaling may have been
activated by other mechanisms, such as a variety of cell regulatory
proteins implicated in gene expression, cross-reactivity with an
unknown epitope, or epigenetic means.
In conclusion, owing to the limited case number, especially as
there was only one c-KIT positive case, the occurrence of this single
c-KIT positive case might not be representative of a larger popu-
lation. The low frequency of expression suggests that imatimab
may have a limited value in the management of patients with c-KIT
positive primary adenoca Ut Cx.d Chung Shan Medical University Hospital, No. 110, Sec. 1, Jianguo N. Rd., Taichung
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Figure 1. Histologic features of adenoca Ut Cx [hematoxylin and eosin stain (H&E)] stained sections; case code No. 1-1) typically show (A) moderately differentiated adenocar-
cinoma, characterized by irregular haphazard arrangement of glands and solid nests with cribriform growth pattern. Additionally, there is no apparent desmoplastic stromal re-
action. (H&E stain, 40); (B) a higher magniﬁcation view of the area within the square in A illustrating atypical glandular epithelium with eosinophilic cytoplasm and vacuolated
nuclei. Dispersed mitoses and apoptotic bodies can be readily found. (H and E stain, 200); (C) IHC showing that focal tumor cells with signiﬁcant cytoplasmic staining and
accentuation of membranous c-KIT positivity. The arrow head indicates the mast cells used as an internal positive control. (c-KIT stain, 200); (D) IHC showing the tumor cells with
negative expression of SCF. (SCF stain, 200). IHC¼ immunohistochemistry; SCF¼ stem cell factor.
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